Can AbbVie’s Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation?
Why now
Thesis: Biotech IPO demand tested by ADARx
Catalyst to watch: IPO pricing and first-day trading
Main risk: Valuation and terms unconfirmed
Why it matters
AbbVie backing could validate ADARx's platform and shape biotech IPO pricing appetite.
Sources
- googlenews · news.google.com · 2026-09-28 19:39 UTC